I agree that this site is using cookies. You can find further informations here.
X
Lakhani, Nehal
47  results:
Search for persons X
?
1

Comprehensive Target Engagement by the EZH2 Inhibitor Tulmi..:

Keller, Patricia J. ; Adams, Elizabeth J. ; Wu, Rentian...
Cancer Research.  84 (2024)  15 - p. 2501-2517 , 2024
Link: https://doi.org/10.1158/..
 
?
2

Phase I studies of davoceticept (ALPN-202), a PD-L1-depende..:

Davar, Diwakar ; Cavalcante, Ludimila ; Lakhani, Nehal...
Journal for ImmunoTherapy of Cancer.  12 (2024)  8 - p. e009474 , 2024
Link: https://doi.org/10.1136/..
 
?
3

Phase 1b study to assess the safety, tolerability, and clin..:

Stradella, Agostina ; Johnson, Melissa ; Goel, Sanjay...
Cancer Medicine.  13 (2024)  13 - p. , 2024
Link: https://doi.org/10.1002/..
 
?
4

43001 Phase 1 study of fianlimab, a human lymphocyte activa..:

Hamid, Omid ; Weise, Amy ; Lewis, Karl D....
Journal of the American Academy of Dermatology.  89 (2023)  3 - p. AB207 , 2023
Link: https://doi.org/10.1016/..
 
?
5

Phase 1 study of fianlimab, a human lymphocyte activation g..:

Hamid, Omid ; Lewis, Karl ; Weise, Amy...
SKIN The Journal of Cutaneous Medicine.  7 (2023)  2 - p. s179 , 2023
Link: https://doi.org/10.25251..
 
?
6

Preclinical Characterization and Phase I Trial Results of I..:

Subbiah, Vivek ; Chawla, Sant P. ; Conley, Anthony P....
Clinical Cancer Research.  29 (2023)  16 - p. 2988-3003 , 2023
Link: https://doi.org/10.1158/..
 
?
7

Updated Results from the Phase 1 Expansion Study of Upifita..:

Richardson, Debra ; Hamilton, Erika ; Barve, Minal...
Gynecologic Oncology.  166 (2022)  - p. S48 , 2022
Link: https://doi.org/10.1016/..
 
?
8

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzu..:

Aggarwal, Charu ; Prawira, Amy ; Antonia, Scott...
Journal for ImmunoTherapy of Cancer.  10 (2022)  4 - p. e004424 , 2022
Link: https://doi.org/10.1136/..
 
?
9

Upgrade: Phase 1 combination trial of the NaPi2b-directed d..:

Lakhani, Nehal ; Burns, Timothy ; Barve, Minal...
Gynecologic Oncology.  166 (2022)  - p. S285 , 2022
Link: https://doi.org/10.1016/..
 
?
10

CTNI-49. EARLY SIGNAL OF ACTIVITY FROM A PHASE 2 STUDY OF S..:

Iwamoto, Fabio ; Gondi, Vinai ; Butowski, Nicholas...
Neuro-Oncology.  24 (2022)  Supplement_7 - p. vii83-vii83 , 2022
Link: https://doi.org/10.1093/..
 
?
11

32 UPGRADE: phase 1 combination trial of the NaPi2b-directe..:

Werner, Theresa L. ; Lakhani, Nehal ; Edenfield, William...
Gynecologic Oncology Reports.  44 (2022)  - p. S16 , 2022
Link: https://doi.org/10.1016/..
 
?
12

Safety and Efficacy of a DNA Oligonucleotide Therapy in Pat..:

Westin, Jason ; Maris, Michael B ; Jacobson, Caron A...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  1 - p. 52-59 , 2022
Link: https://doi.org/10.1016/..
 
?
13

A Phase 2 Study of PNT2258 for Treatment of Relapsed or Ref..:

Harb, Wael ; Lakhani, Nehal J. ; Messmann, Richard..
Clinical Lymphoma Myeloma and Leukemia.  21 (2021)  12 - p. 823-830 , 2021
Link: https://doi.org/10.1016/..
 
?
14

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin)..:

Maitland, Michael L. ; Sachdev, Jasgit C. ; Sharma, Manish R....
Clinical Cancer Research.  27 (2021)  16 - p. 4511-4520 , 2021
Link: https://doi.org/10.1158/..
 
?
15

CTNI-49. PHASE 1 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE A..:

Symeonides, Stefan ; Evans, Jeff ; Arkenau, Hendrik-Tobias...
Neuro-Oncology.  23 (2021)  Supplement_6 - p. vi71-vi71 , 2021
Link: https://doi.org/10.1093/..
 
1-15